Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Britain Courts Anthropic Amid US Defense Department Dispute 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
DURHAM, N.C., Sept. 20, 2017 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 10:55 a.m. ET at the InterContinental New York Barclay Hotel.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. In addition, Chimerix has in early-stage development a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
